顶级华人科学家联合创立，新的分子合作

Takeda is offering Kumquat Biosciences the chance to make more than $1.2 billion biobucks in a new exclusive pact that centers around an unnamed immuno-oncology small molecule inhibitor.$武田制药(TAK)$

Kumquat will receive up to $130 million in near-term payments and potentially more than $1.2 billion if all future clinical, regulatory, and commercial milestones are achieved during the term of the agreement plus tiered royalties on potential net sales of any commercial products resulting from this license.